John Higgins

Dr. John Higgins is laying the groundwork for future advancements in the field of bioengineering, with a particular focus on blood flow analysis and microfluidics. As a faculty member within the Systems, Synthetic, and Quantitative Biology program at Harvard Medical School, Dr. Higgins is at the forefront of research into the microfluidics of sickle cell anemia. His innovative work involves the use of a microfluidic device to meticulously analyze patient blood flow under varying oxygen levels, providing critical insights into the disease. Dr. Higgins's research has revealed significant differences in conductance between patients, which could play a pivotal role in determining the severity of the disease, categorizing patients, and developing novel therapeutic approaches. His findings are not only crucial for advancing our understanding of sickle cell disease but also hold promise for improving patient outcomes through more personalized treatment strategies. In addition to his research, Dr. Higgins is deeply involved in the broader academic community at Harvard, contributing to the program's emphasis on computational biology, mHealth, and plant and microbial biology. His work is characterized by a strong commitment to advancing these fields through teaching, research, and collaborative efforts with colleagues and students alike. Dr. Higgins's dedication to bioengineering is evident in his interdisciplinary approach, which bridges the gap between theoretical research and practical applications. His contributions are helping to shape the future of bioengineering, with the potential to impact a wide range of medical and biological challenges. Through his work, Dr. Higgins continues to inspire the next generation of scientists and engineers, fostering an environment of innovation and discovery. His efforts are not only advancing the field of bioengineering but also paving the way for new breakthroughs in the understanding and treatment of complex diseases like sickle cell anemia.